Originalpublikationen
Arnold MB, ...Riemekasten G, et al. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2018 Jan 1;57(1):152-157.doi: 10.1093/rheumatology/kex396
Herrick AL, ..., Riemekasten G, et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. 2018 Apr;77(4):563-570. doi:10.1136/annrheumdis-2017-211912
Recke A, Regensburger AK, Weigold F, Müller A, Heidecke H, Marschner G, Hammers CM, Ludwig RJ, Riemekasten G. Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping
Indicates Increased Binding to Cytoplasmic Domains of CXCR3. Front Immunol. 2018 Mar 22;9:428. doi: 10.3389/fimmu.2018.00428. eCollection 2018
Reviews, Letters, Reports, etc.
Lamprecht P, Kerstein A, Klapa S, Schinke S, Karsten CM, Yu X, Ehlers M, Epplen JT, Holl-Ulrich K, Wiech T, Kalies K, Lange T, Laudien M, Laskay T, Gemoll T, Schumacher U, Ullrich S, Busch H, Ibrahim S, Fischer N, Hasselbacher K, Pries R, Petersen F, Weppner G, Manz R, Humrich JY, Nieberding R, Riemekasten G, Müller A. Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides. Front Immunol. 2018 Apr 9;9:680. doi: 10.3389/fimmu.2018.00680. eCollection 2018.